+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
H1N1 Vaccines Market by Product Type, Technology, End User, Distribution Channel, Dosage Form, Age Group - Global Forecast to 2030- Product Image
H1N1 Vaccines Market by Product Type, Technology, End User, Distribution Channel, Dosage Form, Age Group - Global Forecast to 2030- Product Image
Sale

H1N1 Vaccines Market by Product Type, Technology, End User, Distribution Channel, Dosage Form, Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904545
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The H1N1 Vaccines Market grew from USD 13.45 billion in 2024 to USD 18.42 billion in 2025. It is expected to continue growing at a CAGR of 35.61%, reaching USD 83.70 billion by 2030.

Setting the Stage for H1N1 Vaccine Developments

The H1N1 vaccine landscape has undergone significant transformation in recent years, driven by both scientific breakthroughs and shifting public health priorities. An evolving understanding of immunological responses to influenza A strains has propelled advancements in vaccine formulations, leading to broader efficacy and improved safety profiles. Innovations in recombinant technology and alternative production platforms have redefined what is possible, enabling faster scale-up of vaccine manufacturing during outbreak scenarios. This introduction provides a concise yet comprehensive overview of the forces reshaping the H1N1 immunization sphere, setting the stage for deeper exploration of market drivers, regulatory influences and emerging opportunities.

Public awareness of pandemic preparedness has surged as health authorities and governments prioritize resilience against future influenza threats. This heightened focus has led to strengthened supply chains, increased investment in next-generation vaccine platforms and expanded collaboration among stakeholders. As national immunization programs strive to protect vulnerable populations, the interplay of policy, science and commercial strategy has never been more critical. This section outlines the context for subsequent analysis, highlighting why decision makers must stay informed and agile to navigate a market that is both complex and critical to global health security.

Navigating Pivotal Changes Shaping the H1N1 Vaccine Arena

The past decade has witnessed transformative shifts in how H1N1 vaccines are researched, produced and distributed. A notable evolution is the rise of cell-based manufacturing, which circumvents constraints tied to egg supplies and reduces the risk of egg-adapted mutations. Simultaneously, the adoption of recombinant technologies has ushered in a new era of precision immunogens, offering the potential for broader cross-protection against diverse influenza A subtypes. This convergence of technological innovation and regulatory agility has set the industry on a trajectory toward faster response times and improved vaccine match.

Beyond technological advances, the landscape has been reshaped by emerging partnerships between public health agencies and private biopharma organizations. These alliances have streamlined clinical trial pathways and accelerated licensure processes under emergency use authorizations. The collective experience of responding to H1N1 outbreaks has fostered a culture of collaboration, where data sharing and joint investment initiatives are now commonplace. As a result, manufacturers can navigate regulatory expectations more efficiently, bringing updated vaccines to market with unprecedented speed while maintaining rigorous safety standards.

Assessing the 2025 US Tariff Impact on Vaccine Supply Chains

In 2025, the introduction of new tariffs on pharmaceutical inputs and finished vaccine products has injected fresh complexity into the H1N1 supply chain. Raw materials sourced from international suppliers have become more expensive, compelling manufacturers to reevaluate sourcing strategies and optimize production workflows. The cumulative effect of these duties has been particularly pronounced for facilities relying on egg-based antigen production, where import costs for eggs and ancillary reagents have risen sharply. To mitigate margin erosion, several manufacturers are exploring domestic supplier partnerships and investing in alternative platforms that are less tariff-exposed.

The tariff regime has also influenced pricing strategies for end users. Public health programs facing tighter budgets are negotiating more stringent volume discounts, while private buyers have become increasingly cost sensitive. In response, vaccine producers are leveraging scale efficiencies and enhanced process automation to preserve competitive pricing without sacrificing quality. Although short-term profit pressures have surfaced, the drive toward tariff resilience is accelerating diversification of manufacturing footprints. This pivot promises to strengthen long-term supply security by reducing dependence on any single production geography.

Unveiling Critical Market Segments Driving Vaccine Uptake

The H1N1 vaccine market can be dissected across multiple dimensions, each revealing distinct drivers of adoption and competitive advantage. Through the lens of product type segmentation, inactivated vaccines dominate with subcategories that span cell-based, egg-based and recombinant platforms, while live attenuated offerings rely exclusively on egg-based production. Technological segmentation underscores the strategic importance of cell-based and recombinant methods in mitigating supply chain vulnerabilities. From an end user perspective, clinics, hospitals and public health centers exhibit varying demand patterns, with mass immunization efforts typically coordinated through large-scale health institutions.

Distribution channel segmentation highlights the evolving role of hospital pharmacies, online platforms and retail pharmacies in delivering H1N1 vaccines to diverse patient populations. Dosage form insights indicate a growing preference for pre-filled syringes due to ease of administration and reduced wastage, although multi-dose vials remain cost-effective for large immunization campaigns. Age group segmentation reveals that adult and senior cohorts drive the highest volume uptake, while pediatric vaccination rates continue to climb as formulations demonstrate improved safety in younger populations. Each segmentation axis offers critical understanding of market dynamics, enabling stakeholders to tailor manufacturing, marketing and distribution strategies with precision.

Key Regional Dynamics Influencing H1N1 Immunization

Regional dynamics exert a powerful influence on H1N1 immunization strategies and resource allocation. In the Americas, a robust framework of national vaccine stockpiles and streamlined regulatory pathways has fostered rapid deployment of updated formulations. Public-private partnerships in North America and Latin America continue to strengthen local manufacturing capabilities, enhancing resilience against global supply disruptions.

In the Europe, Middle East and Africa region, heterogeneous regulatory regimes and variable healthcare infrastructure create both challenges and opportunities. Western Europe’s advanced cold-chain networks support high vaccination coverage, while emerging markets in Eastern Europe and the Middle East are investing in expanded distribution sites to improve rural access. African public health initiatives, bolstered by international funding mechanisms, aim to integrate H1N1 vaccination drives with broader immunization programs to maximize reach and cost-effectiveness.

The Asia-Pacific region stands out for its rapidly expanding biopharmaceutical capacity, particularly in cell-based vaccine production. Countries such as Japan and Australia have established world-class facilities, while emerging players in Southeast Asia are attracting significant foreign direct investment. This regional momentum underscores a shift toward decentralized manufacturing, positioning Asia-Pacific as a key contributor to global H1N1 vaccine supply.

Spotlight on Leading Vaccine Manufacturers

Leading vaccine manufacturers have continued to invest in innovative platforms and strategic alliances to maintain their competitive edge. One major player has focused on expanding its recombinant vaccine pipeline through licensing agreements that accelerate technology transfer to contract manufacturers. Another global leader has prioritized the modular expansion of cell-culture facilities, enabling rapid scale-up in response to sudden demand spikes. A third prominent firm has pursued a dual strategy of optimizing egg-based capacity for cost-sensitive markets while piloting mRNA-inspired approaches aimed at the next generation of influenza vaccines.

Collaborations between large pharmaceutical companies and specialized biotech firms have also shaped the market. These partnerships are driving joint research efforts to improve antigenic matching and broaden immune coverage. Strategic acquisitions of manufacturing sites and R&D centers have bolstered capabilities in key regions, enhancing supply chain redundancy. Through these concerted efforts, major stakeholders are positioning themselves to address evolving public health needs while navigating the complexities of regulatory compliance and tariff pressures.

Strategic Imperatives for Industry Advancement

Industry leaders should prioritize flexible manufacturing strategies that incorporate multiple production platforms to mitigate supply chain risks. Establishing cell-based and recombinant capacities alongside existing egg-based infrastructure will ensure rapid response capabilities during outbreak scenarios. Strengthening relationships with domestic raw material suppliers can further reduce exposure to tariff fluctuations and international logistics challenges.

Marketing efforts must emphasize real-world evidence of vaccine effectiveness and safety across different age cohorts. Tailored communication campaigns that highlight improved administration formats and targeted dosing will resonate with healthcare providers and end users. In parallel, forging alliances with public health agencies to secure advance purchase agreements can stabilize revenue streams and support large-scale immunization programs. Finally, embracing digital health solutions-from cold-chain monitoring to online patient engagement tools-will enhance distribution efficiency and build trust among stakeholders.

Rigorous Approach Underpinning Our Analysis

Our analysis draws upon a comprehensive blend of primary and secondary research methodologies. Primary insights were gathered through in-depth interviews with key opinion leaders, policymakers and senior executives across vaccine manufacturers, contract development organizations and regulatory bodies. These perspectives provided direct visibility into strategic priorities, operational challenges and emerging investment trends.

Secondary research encompassed a rigorous review of scientific literature, regulatory filings and corporate disclosures. Data validation was achieved by cross-referencing information from trade associations, public health agencies and market intelligence databases. A structured framework guided our segmentation analysis, ensuring consistent evaluation across product types, technologies, end users, distribution channels, dosage forms and age groups. Peer review sessions and expert panel consultations further enhanced the credibility of our findings, resulting in a robust and actionable body of insights.

Converging Insights and Future Perspectives

The evolving H1N1 vaccine landscape is defined by technological innovation, regulatory agility and strategic collaboration among stakeholders. As manufacturers adapt to new tariff regimes and shifting end-user demands, the ability to pivot manufacturing platforms and distribution models will prove decisive. Regional market characteristics underscore the importance of tailored strategies that align with local infrastructure and policy environments.

Looking ahead, sustained investment in advanced platforms such as recombinant and cell-based technologies will support preparedness for future influenza challenges. By leveraging real-world evidence and strengthening public-private partnerships, industry participants can enhance vaccine accessibility and public health outcomes. Ultimately, the confluence of scientific progress and strategic execution will determine the trajectory of the H1N1 immunization market.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Inactivated Vaccine
      • Cell Based
      • Egg Based
      • Recombinant
    • Live Attenuated Vaccine
      • Egg Based
  • Technology
    • Cell Based
    • Egg Based
    • Recombinant
  • End User
    • Clinics
    • Hospitals
    • Public Health Centers
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Dosage Form
    • Multi-Dose Vials
    • Pre-Filled Syringes
  • Age Group
    • Adults
    • Children
    • Seniors
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Sanofi Pasteur SA
  • GlaxoSmithKline plc
  • CSL Seqirus Pty Ltd
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Moderna, Inc.
  • Bharat Biotech International Limited
  • Bavarian Nordic A/S
  • Panacea Biotec Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. H1N1 Vaccines Market, by Product Type
8.1. Introduction
8.2. Inactivated Vaccine
8.2.1. Cell Based
8.2.2. Egg Based
8.2.3. Recombinant
8.3. Live Attenuated Vaccine
8.3.1. Egg Based
9. H1N1 Vaccines Market, by Technology
9.1. Introduction
9.2. Cell Based
9.3. Egg Based
9.4. Recombinant
10. H1N1 Vaccines Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Hospitals
10.4. Public Health Centers
11. H1N1 Vaccines Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. H1N1 Vaccines Market, by Dosage Form
12.1. Introduction
12.2. Multi-Dose Vials
12.3. Pre-Filled Syringes
13. H1N1 Vaccines Market, by Age Group
13.1. Introduction
13.2. Adults
13.3. Children
13.4. Seniors
14. Americas H1N1 Vaccines Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa H1N1 Vaccines Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific H1N1 Vaccines Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Sanofi Pasteur SA
17.3.2. GlaxoSmithKline plc
17.3.3. CSL Seqirus Pty Ltd
17.3.4. Novartis AG
17.3.5. Pfizer Inc.
17.3.6. Takeda Pharmaceutical Company Limited
17.3.7. Moderna, Inc.
17.3.8. Bharat Biotech International Limited
17.3.9. Bavarian Nordic a/S
17.3.10. Panacea Biotec Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. H1N1 VACCINES MARKET MULTI-CURRENCY
FIGURE 2. H1N1 VACCINES MARKET MULTI-LANGUAGE
FIGURE 3. H1N1 VACCINES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL H1N1 VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL H1N1 VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL H1N1 VACCINES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL H1N1 VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 16. GLOBAL H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 18. GLOBAL H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES H1N1 VACCINES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES H1N1 VACCINES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. H1N1 VACCINES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. H1N1 VACCINES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. H1N1 VACCINES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL H1N1 VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL H1N1 VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL H1N1 VACCINES MARKET SIZE, BY CELL BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL H1N1 VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL H1N1 VACCINES MARKET SIZE, BY CELL BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL H1N1 VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL H1N1 VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL H1N1 VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL H1N1 VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL H1N1 VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL H1N1 VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL H1N1 VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL H1N1 VACCINES MARKET SIZE, BY MULTI-DOSE VIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL H1N1 VACCINES MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL H1N1 VACCINES MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL H1N1 VACCINES MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL H1N1 VACCINES MARKET SIZE, BY SENIORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES H1N1 VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 52. CANADA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 53. CANADA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 54. CANADA H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 55. CANADA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 56. CANADA H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. CANADA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. CANADA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 59. CANADA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 60. MEXICO H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 61. MEXICO H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 62. MEXICO H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 63. MEXICO H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 64. MEXICO H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. MEXICO H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. MEXICO H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 67. MEXICO H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 93. UNITED KINGDOM H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 101. GERMANY H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 102. GERMANY H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 103. GERMANY H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 104. GERMANY H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 105. GERMANY H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. GERMANY H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. GERMANY H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 108. GERMANY H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 109. FRANCE H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 110. FRANCE H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 111. FRANCE H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 112. FRANCE H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 113. FRANCE H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. FRANCE H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. FRANCE H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 116. FRANCE H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 125. ITALY H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 126. ITALY H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 127. ITALY H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 128. ITALY H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 129. ITALY H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. ITALY H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. ITALY H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 132. ITALY H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 133. SPAIN H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 134. SPAIN H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 135. SPAIN H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 136. SPAIN H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 137. SPAIN H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. SPAIN H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. SPAIN H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 140. SPAIN H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 149. SAUDI ARABIA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 150. SAUDI ARABIA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 151. SAUDI ARABIA H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 157. SOUTH AFRICA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 158. SOUTH AFRICA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 165. DENMARK H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 166. DENMARK H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 167. DENMARK H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 168. DENMARK H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 169. DENMARK H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. DENMARK H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. DENMARK H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 172. DENMARK H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 181. QATAR H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 182. QATAR H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 183. QATAR H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 184. QATAR H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 185. QATAR H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. QATAR H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. QATAR H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 188. QATAR H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 189. FINLAND H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 190. FINLAND H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 191. FINLAND H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 192. FINLAND H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 193. FINLAND H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. FINLAND H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 195. FINLAND H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 196. FINLAND H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 197. SWEDEN H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 198. SWEDEN H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 199. SWEDEN H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 213. EGYPT H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 214. EGYPT H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 215. EGYPT H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 216. EGYPT H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 217. EGYPT H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. EGYPT H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. EGYPT H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 220. EGYPT H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 221. TURKEY H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 222. TURKEY H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 223. TURKEY H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 224. TURKEY H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 225. TURKEY H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. TURKEY H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. TURKEY H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 228. TURKEY H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 229. ISRAEL H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 230. ISRAEL H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 231. ISRAEL H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 237. NORWAY H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 238. NORWAY H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 239. NORWAY H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 240. NORWAY H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 241. NORWAY H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. NORWAY H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. NORWAY H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 244. NORWAY H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 245. POLAND H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 246. POLAND H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 247. POLAND H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 248. POLAND H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 249. POLAND H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. POLAND H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. POLAND H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 252. POLAND H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 253. SWITZERLAND H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 261. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 270. CHINA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 271. CHINA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 272. CHINA H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 273. CHINA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 274. CHINA H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 275. CHINA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 276. CHINA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 277. CHINA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 278. INDIA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 279. INDIA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 280. INDIA H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 281. INDIA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 282. INDIA H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 283. INDIA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 284. INDIA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 285. INDIA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 286. JAPAN H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 287. JAPAN H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 288. JAPAN H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 289. JAPAN H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 290. JAPAN H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 291. JAPAN H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 292. JAPAN H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 293. JAPAN H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 294. AUSTRALIA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 295. AUSTRALIA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 296. AUSTRALIA H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 297. AUSTRALIA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 298. AUSTRALIA H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. AUSTRALIA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 302. SOUTH KOREA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 303. SOUTH KOREA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 304. SOUTH KOREA H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 305. SOUTH KOREA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 306. SOUTH KOREA H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 307. SOUTH KOREA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 309. SOUTH KOREA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 310. INDONESIA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 311. INDONESIA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 312. INDONESIA H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 313. INDONESIA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 314. INDONESIA H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 315. INDONESIA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 317. INDONESIA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 318. THAILAND H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 319. THAILAND H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 320. THAILAND H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 321. THAILAND H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 322. THAILAND H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 323. THAILAND H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 324. THAILAND H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 325. THAILAND H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 326. PHILIPPINES H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 327. PHILIPPINES H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 328. PHILIPPINES H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 329. PHILIPPINES H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 330. PHILIPPINES H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 331. PHILIPPINES H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 332. PHILIPPINES H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 333. PHILIPPINES H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 334. MALAYSIA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 335. MALAYSIA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 336. MALAYSIA H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 337. MALAYSIA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 338. MALAYSIA H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 339. MALAYSIA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 340. MALAYSIA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 341. MALAYSIA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 342. SINGAPORE H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 343. SINGAPORE H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 344. SINGAPORE H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 345. SINGAPORE H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 346. SINGAPORE H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 347. SINGAPORE H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 348. SINGAPORE H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 349. SINGAPORE H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 350. VIETNAM H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 351. VIETNAM H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 352. VIETNAM H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 353. VIETNAM H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 354. VIETNAM H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 355. VIETNAM H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 356. VIETNAM H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 357. VIETNAM H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 358. TAIWAN H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 359. TAIWAN H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2030 (USD MILLION)
TABLE 360. TAIWAN H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 361. TAIWAN H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 362. TAIWAN H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 363. TAIWAN H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL

Companies Mentioned

The companies profiled in this H1N1 Vaccines market report include:
  • Sanofi Pasteur SA
  • GlaxoSmithKline plc
  • CSL Seqirus Pty Ltd
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Moderna, Inc.
  • Bharat Biotech International Limited
  • Bavarian Nordic A/S
  • Panacea Biotec Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages180
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 18.42 Billion
Forecasted Market Value ( USD ) by 2030 $ 83.7 Billion
Compound Annual Growth Rate35.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

H1N1 Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

H1N1 Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 186 Pages
  • Global
From
H1N1 Vaccines Market Report by Vaccine Type (Intramuscular, Intranasal, Intradermal), Market Type (Public, Private), and Region 2025-2033 - Product Image

H1N1 Vaccines Market Report by Vaccine Type (Intramuscular, Intranasal, Intradermal), Market Type (Public, Private), and Region 2025-2033

  • Report
  • 143 Pages
  • Global
From
H1N1 Vaccine Market Report 2025 - Product Image

H1N1 Vaccine Market Report 2025

  • Report
  • 200 Pages
  • Global
From
H1N1 Vaccines - Global Strategic Business Report - Product Image

H1N1 Vaccines - Global Strategic Business Report

  • Report
  • 268 Pages
  • Global
From
India Influenza Vaccine Market, Region, Competition, Forecast & Opportunities, 2020-2030F - Product Image

India Influenza Vaccine Market, Region, Competition, Forecast & Opportunities, 2020-2030F

  • Report
  • 85 Pages
  • India
From

About the H1N1 Vaccine Market

The H1N1 Vaccine is a vaccine developed to protect against the H1N1 strain of influenza, also known as swine flu. It is a type of inactivated vaccine, meaning it contains killed virus particles that are unable to cause infection. The vaccine is administered through injection and is recommended for people of all ages. It is especially important for those at high risk of complications from the virus, such as pregnant women, young children, and people with weakened immune systems. The H1N1 Vaccine market is a subset of the larger Vaccines market, which includes a wide range of products designed to protect against infectious diseases. Vaccines are an important tool in public health, as they can help reduce the spread of disease and protect vulnerable populations. Some companies in the H1N1 Vaccine market include Sanofi Pasteur, GlaxoSmithKline, Merck, and Pfizer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.